Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3016 in Japanese Participants With Mild to Moderate Hypertension
NCT07838220Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of IBI3016 in hypertension (HTN) (5 arms), sponsored by Innovent Biologics. Primary endpoint: Number of Participants with Adverse Events. Started Aug 2026; status: recruiting.
02
Drugs
IBI3016
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07838220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838220.